J&J's Esketamine Fails to Meet Endpoint in Phase III Study

Johnson & Johnson JNJ announced data from a phase III study, evaluating its investigational esketamine nasal spray in combination with newly initiated oral antidepressant (NIOD) on patients with treatment-resistant depression as compared to placebo nasal spray plus the NIOD. The study failed to demonstrate statistical significance for the primary endpoint.